Drug Trial Radar · NCT06555237
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Aug 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Medical University of WarsawAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 day, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
Conditions
- Cardiomegaly
- Noonan Syndrome
Interventions
Trametinib tabletDrug
Trametynib orally once daily in 0,025mg/kg dose
Standard therapyDrug
Disopiramide and Beta blockers orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effectiveness of the trametynib treatment on cardiac hyperthropyTime frame: 1 year
- Effectiveness of the trametynib treatment on laboratory enzymes levelsTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Paediatrics, The Medical University of Warsaw, Poland
Warsaw, Poland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.